Tuberculosis vaccine development: Shifting focus amid increasing development challenges.

about

A review of clinical models for the evaluation of human TB vaccines.Heat-Shock Protein gp96 Enhances T Cell Responses and Protective Potential to Bacillus Calmette-Guérin Vaccine.DNA vaccines 2014 meeting: Highlights and overview.

P2860

Q38711772-BDB05D7B-2BFE-482F-8C3E-B9618DFE237D Q40612933-6F2BA337-71A5-4084-BF08-EB1C51318339 Q43185231-044D4F1D-4D66-478B-BD63-66EF0E8488AC

P2860

Tuberculosis vaccine development: Shifting focus amid increasing development challenges.

Item

http://www.wikidata.org/entity/Q36256304

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年学术文章

@wuu

2015年学术文章

@zh-cn

2015年学术文章

@zh-hans

2015年学术文章

@zh-my

2015年学术文章

@zh-sg

2015年學術文章

@yue

2015年學術文章

@zh

2015年學術文章

@zh-hant

name

Tuberculosis vaccine development: Shifting focus amid increasing development challenges.

@ast

Tuberculosis vaccine development: Shifting focus amid increasing development challenges.

@en

type

Item

label

Tuberculosis vaccine development: Shifting focus amid increasing development challenges.

@ast

Tuberculosis vaccine development: Shifting focus amid increasing development challenges.

@en

prefLabel

Tuberculosis vaccine development: Shifting focus amid increasing development challenges.

@ast

Tuberculosis vaccine development: Shifting focus amid increasing development challenges.

@en

P1476

Tuberculosis vaccine development: Shifting focus amid increasing development challenges.

@en

P2093

A J Graves

http://www.w3.org/2001/XMLSchema#string

D A Hokey

http://www.w3.org/2001/XMLSchema#string

P2860

Tuberculosis and HIV co-infection

Th17 cells in autoimmune and infectious diseases

Tuberculosis in Africa — Combating an HIV-Driven Crisis

Severe mycobacterial and Salmonella infections in interleukin-12 receptor-deficient patients

Failure of the Mycobacterium bovis BCG vaccine: some species of environmental mycobacteria block multiplication of BCG and induction of protective immunity to tuberculosis

Safety and immunogenicity of a new tuberculosis vaccine, MVA85A, in healthy adults in South Africa

CD1 and mycobacterial lipids activate human T cells

Synthetic DNA vaccine strategies against persistent viral infections

MR1-restricted mucosal associated invariant T (MAIT) cells in the immune response to Mycobacterium tuberculosis

Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent

P304

1910-1916

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1080/21645515.2015.1040955

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2015-06-30T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

279457016

http://www.w3.org/2001/XMLSchema#string

P698

26125249

http://www.w3.org/2001/XMLSchema#string

P932

4635864

http://www.w3.org/2001/XMLSchema#string

Tuberculosis vaccine development: Shifting focus amid increasing development challenges.

about

P2860

P2860

Tuberculosis vaccine development: Shifting focus amid increasing development challenges.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P5875

P698

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P5875

P698

P932